Navigation Links
Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
Date:3/12/2010

ny's financial position, results of operations, market position, product development and business strategy, as well as estimates of future total revenues, future expenses, future net income and future earnings per share.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may" "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this presentation. These factors include, but are not limited to: our ability to successfully develop, commercialize and market new products; timing and results of pre-clinical or clinical trials on new products; our ability to obtain regulatory approval of any of our pipeline products; competition for the business of our branded and generic products, and in connection with our acquisition of rights to intellectual property assets; market acceptance of our future products; government regulation of the pharmaceutical industry;  our dependence on a small number of products;   our dependence on outside manufacturers for the manufacture of a majority of our products;  our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of narcotics in most of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; the successful efforts of manufacturers of branded pharmaceuticals to use litigation and legislative and regulatory efforts to limit the use of generics and
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... NVAX ), a clinical-stage vaccine company, announced today ... presenting at the ROTH 23rd Annual OC Growth Stock Conference ... The Ritz Carlton, Laguna Niguel, CA.  A live audio-only webcast ... website at www.novavax.com under Investors/Events, and a replay ...
... and LONDON, March 11, 2011 Tolerx, ... 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 ... of change in C-peptide at month 12 in patients ... Following preliminary review of the data, no new or ...
Cached Medicine Technology:Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 2Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 3Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint 4
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and cooking food comes ... at a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now ... Recipes from My Persian Kitchen with the world. , Since Americans tend to be ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... 30 Last week, the Board of,Directors of ... plan that will serve as a roadmap for ... the association must undertake to,enable it to fulfill ... for,patients throughout Jordan., The development of the ...
... among ideas that could lead to new treatments, experts ... reports on very different approaches to treating Alzheimer,s disease ... mind-robbing condition, experts say. , A trio of studies ... Alzheimer,s Association 2008 International Conference on Alzheimer,s Disease in ...
... fathers, researchers say , , WEDNESDAY, July 30 (HealthDay News) ... be predisposed to the mind-robbing condition, a new study ... how the brain handles sugar -- something that,s probably ... researchers say. , "Overall, these findings show that their ...
... announced,the recipients of the Labs Are Vital(TM) ... of Clinical Chemistry (AACC) Annual Meeting., ... of Nevada, Las Vegas, Nev.; University of ... Texas, Reading Area Community,College, Reading, Penn., Southeastern ...
... Casey Family Programs has,hired Page B. Walley. Ph.D., ... as managing director for strategic consulting to promote,safe ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070116/CASEYFAMILYLOGO ), Walley ... since January,2004. He oversaw improvements in the state,s ...
... Exchange Symbol: CYT, MONTREAL, July 30 /PRNewswire-FirstCall/ ... in cryotherapy products to treat cardiac,arrhythmias, today announced ... present a corporate update at the BMO Focus ... Wednesday, August,6th at 8:30 a.m. (ET) in Room ...
Cached Medicine News:Health News:Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future 2Health News:Advances Made Against Alzheimer's Disease 2Health News:Advances Made Against Alzheimer's Disease 3Health News:Moms With Alzheimer's May Pass on Risk to Kids 2Health News:Moms With Alzheimer's May Pass on Risk to Kids 3Health News:Abbott Donates Diagnostic Instruments As Part of the 'Labs Are Vital(TM)' Initiative 2Health News:Casey Family Programs Names Alabama's Walley Managing Director for Strategic Consulting 2Health News:Casey Family Programs Names Alabama's Walley Managing Director for Strategic Consulting 3
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: